Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Unknown 3Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Rare Tumour 1Lung Diseases, Interstitial 1Hodgkin Disease 1Her2-negative Metastatic Breast Cancer 1HER2-positive Advanced Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Etoposide 3Drug Therapy 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2cemiplimab 2Vincristine 2Temozolomide 2Platinum 2Paclitaxel 2Injections 2Immunotherapy, Adoptive 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Docetaxel 2Carboplatin 2Capecitabine 2Bevacizumab 2venetoclax 1relmacabtagene autoleucel 1pomalidomide 1pirtobrutinib 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Vinorelbine × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡